Bridge Bank’s Life Sciences Group Hires Phillip Ho in San Francisco

SAN FRANCISCO — Bridge Bank today announced that Phillip “Phil” Ho has joined its Life Sciences Group as senior vice president.

In his new role, Phil will support Bridge Bank’s Life Sciences Group in its mission to help companies in the industry bring their visions to market, working specifically with clients in the San Francisco Bay Area and the Pacific Northwest. Based in San Francisco, he will also be responsible for building and maintaining relationships with venture capital firms and other equity sponsors that help companies establish essential connections to financial institutions, such as Bridge Bank.

“Phil’s wealth of experience and keen insights make him the ideal candidate to lead our business development efforts throughout the Bay Area and the Northwest,” said Bill Wickline, managing director of Bridge Bank’s Life Sciences Group. “With Phil on board, we are poised to remain committed to the life sciences sector and forge new avenues of growth and collaboration to help companies at all stages of their life cycle.” 

Phil has extensive experience in the life sciences sector. Before joining Bridge Bank, he was executive director and senior life science banker at JP Morgan Chase, where he developed relationships with key Bay Area venture capitalists, early-stage companies and opinion leaders. Previously, he was managing director of venture banking originations for life science and health care at Pacific Western Bank in New York. Additionally, he brings a wealth of experience in leveraged finance in the health care and biopharma industries at BMO Capital Markets, Credit Suisse First Boston and GE Capital.

“I am excited to join Bridge Bank’s dynamic life sciences group and contribute to its forward-thinking approach to fostering innovation,” said Phil. “Bridge Bank’s commitment to supporting breakthrough advancements in the industry aligns perfectly with my passion for driving business growth. I look forward to bringing my skills and expertise to cultivate meaningful relationships and contribute to life sciences companies’ success.”